CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing neflamapimod, a small-molecule drug candidate aimed at neurodegenerative diseases, especially dementia with Lewy bodies (DLB). The company’s approach centers on reducing brain inflammation and p38α-driven synaptic dysfunction, which it believes contributes to cognitive and motor decline in degenerative brain disorders. CervoMed was formed through a 2023 reverse recapitalization and changed its name from Diffusion Pharmaceuticals Inc. after the merger. It is headquartered in Boston and currently has no approved products or commercial sales infrastructure, so its business is concentrated on research, clinical development, and eventual partnering or commercialization options.
−673,1 %
−58,9 %
4.91
4.91
| % | |
|---|---|
| Lead drug candidate development | 0% Development of neflamapimod as a treatment for DLB and other CNS diseases. |
| Clinical trial operations | 0% Execution of nonclinical studies and clinical trials, including the RewinD-LB program. |
| Grant-funded research revenue | 100% Revenue recognized from the NIA Grant as qualifying expenses are incurred. |
| Intellectual property and partnering | 0% Patent protection, development optionality, and potential licensing or collaboration arrangements. |
CervoMed does not currently sell an approved product, so it has no traditional commercial customer base today...
The NIA Grant funds qualifying research and clinical development expenses, making the U.S. government a current source of operating support.
CROs, nonclinical testing organizations, consultants, and CDMOs buy-side counterparties that enable trial execution and manufacturing of clinical materials.
Strategic collaborators or licensees that could help fund, develop, or commercialize neflamapimod across indications.
Neurologists, hospitals, and patients in DLB and other CNS diseases would be the end-market if the product is approved.
CervoMed is a U.S.-based company with its principal office in Boston, Massachusetts, and its corporate and development...
CervoMed’s near-term strategy is to advance neflamapimod through clinical development, including a planned Phase 3...
Clinical proof-of-concept and Phase 3 execution are the main value drivers for a single-asset biotech with no product revenue.
The company expects to need additional capital to fund operations and development, making financing continuity essential to execution.
With no internal sales infrastructure, future value realization may depend on licensing or strategic collaborations.
Patent protection and reliable clinical supply manufacturing are necessary to support regulatory progress and future market exclusivity.
CervoMed faces the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and the possibility...
The company states that existing cash and marketable securities may not fund operations for 12 months, so financing is required to continue development.
The asset is still in development, and failure to demonstrate efficacy or safety would undermine the company’s core value proposition.
The company does not own manufacturing facilities and depends on CROs/CDMOs, which can cause delays, quality issues, or higher costs.
Larger pharmaceutical firms and other biotech companies may develop more effective or faster-approved therapies.
A breach could expose confidential trial data or IP and disrupt development activities.
The company notes ongoing matters and the possibility of subpoenas or claims, which can be costly and distracting.
CARL · Surgical & Medical Instruments & Apparatus
CRVS · Pharmaceutical Preparations
CELZ · Biological Products, (No Diagnostic Substances)
CGON · Biological Products, (No Diagnostic Substances)
CERS · Surgical & Medical Instruments & Apparatus
Cerus Corp develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform used to treat donated blood components before transfusion.
RNXT · Pharmaceutical Preparations
: 28.4.2026